Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris
This article was originally published in The Pink Sheet Daily
The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.
You may also be interested in...
Alexion’s treatment for a rare blood disease met CHMP’s criteria for accelerated review.
Soliris is slated to launch within two weeks from its March 16 approval.
The APEX-AMI study of pexelizumab in patients with acute myocardial infarction failed to meet its endpoint of reduction in mortality.